Arbutus Biopharma (ABUS) Long-Term Deferred Tax (2012 - 2013)
Arbutus Biopharma's (ABUS) quarterly Long-Term Deferred Tax came in at $16.3 million in Q4 2013, up 3.59% year-on-year from $15.7 million in Q4 2012, and up 3.59% quarter-over-quarter from $15.7 million in Q4 2012.
Arbutus Biopharma (ABUS) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Arbutus Biopharma has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $16.3 million for Q4 2013.
- Long-Term Deferred Tax for Q4 2013 came in at $16.3 million, up 3.59% year-over-year; the trailing twelve-month figure through Dec 2013 was $16.3 million (up 3.59% YoY), and the FY2013 annual result was $16.3 million, up 3.59% from the prior year.
- Long-Term Deferred Tax came in at $16.3 million for Q4 2013 at Arbutus Biopharma, up from $15.7 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $16.3 million in Q4 2013 to a low of $15.7 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 16.30 Mn |
| Dec 31, 2012 | 15.74 Mn |